Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 482 participants.
Also called NCT03397121
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 482 participants
- Sponsor
- Registry
-
NCT03397121 -
2017-002472-30
-
- Other papers using this trial's data
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Czechia, Denmark, Netherlands, South Africa, Spain, Sweden
- Registry status
- Completed
Technical summary
Registry record NCT03397121. Randomized; double masking; primary purpose treatment. Start 2017-11-28 (actual); primary completion 2019-08-27 (actual). Results posted on 2020-10-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)
- Acronym
- ORION-9
- Condition
- Heterozygous Familial Hypercholesterolemia
- Condition
- Elevated Cholesterol
- Intervention (Drug)
- Inclisiran
- Intervention (Drug)
- Placebo
- Lead sponsor
- The Medicines Company
Record details
- Record id
cardio:ct-nct03397121- Content hash
c6ab3774e2b3d16df83fdc0977f0469a2b6dd9bacf0d78fe3357703ff4654215